Strides Arcolab gets USFDA nod for generic skin disease cream

Tags: Companies
Drug firm Strides Arcolab has received approval from the US health regulator to market its generic Imiquimod cream, used in treating skin diseases, in the American market.

The Bangalore-based company has received approval from the US Food and Drug Administration (USFDA) for Imiquimod cream, Strides Arcolab Ltd said in a statement.

"This is the first product approval from Beltapharm, the company's USFDA approved semi-solids facility in Milan, Italy. The product will be marketed directly by Strides in the US market," it added.

According to IMS data, the US market for generic Imiquimod cream is around USD 140 million.

Imiquimod cream is a topical skin cream indicated for the treatment of certain types of actinic keratoses (precancerous skin lesions) on the face or scalp, external genital and perianal warts in patients aged 12 years and more.

Strides shares were trading at Rs 624.75 apiece on the BSE, up 3.46 per cent from its previous close.

EDITORIAL OF THE DAY

  • Profit motive, not arbitrary pricing, should be guiding principle for the railways

    The freight hike for coal by the railways raises a serious question about the government’s penchant for price manipulation and administered pricing

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Susan Visvanathan

A world that is constantly at war

THE 19th century posed specific problems to theorists about how ...

Jemima Raman

Things one learns on a potter's wheel

As things go, watching a shape emerge from a blob ...

Shona Adhikari

Masterpieces on the auction block

A rather important auction of 20th century Indian art by ...